| OBJECTIVE:To access the clinical efficacy and safety of lactobacillus for women with bacterial vaginosis.METHODS:We searched CENTRAL(The Cochrane Library 2010, Issue 1). PubMed (1966.01-2010.01). EMBASE (1974.01-2010.01),CBMdisc (1978.01-2010.01),CNKI (1979.01-2010.01),VIP (1989.01-2010.01) and WANFANG DATABASE(1989.01-2010.01). Relevant journals were also hand searched to January 2010. We collected randomized controlled trials (RCT) on lactobacillus for women with bacterial vaginosis. Study selection and quality assessment, data extraction and analyses were undertaken by two reviewers independently according to the Cochrane Handbook for Systematic Reviews of interventions. Meta-analyses were also performed.RESULTS:Sixteen RCTs involving 1843 eligible patients were included. Twelve trials (1259 patients) compared lactobacillus with metronidazole; three trials (193 patients) compared combination with metronidazole; six trials (517 patients) compared sequential medication with metronidazole; tow trials (84 patients) compared combination with sequential medication. The Meta-analyses showed that lactobacillus applied the same effect and safety compared with metronidazole and using both could reduce the recurrent rate. The route and vehicle of administration are like to be irrelevant.CONCLUSION:Lactobacillus applied the same effect compared with metronidazole and there was no evidence to say it is unsafe. Using both could reduce the recurrent rate of BV. |
PDF Full Text Request